Everolimus Related Compound 3 Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

(2S)?-1-?[2-?[(2R,?3R,?6S)?-?6-?[(2S,?3E,?5E,?7E,?9S,?11R)?-?2,?13-?Dimethoxy-?3,?9,?11-?trimethyl-?12-?oxo-?3,?5,?7-?tridecatrien-?1-?yl]?tetrahydro-?2-?hydroxy-?3-?methyl-?2H-?pyran-?2-?yl]?-?2-?oxoacetyl]?-?2-?piperidinecarboxylic Acid is an impurity of Sirolimus (R124000) which is an immunosuppressant drug used to prevent rejection in organ transplantation.

Everolimus Related Compound 3 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Everolimus Related Compound 3 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Standardpharm Co. Ltd.	86-714-3992388	overseasales1@yongstandards.com	United States	14332	58
China National Standard Pharmaceutical Corporation Limited	+8615391658522	overseasales@yongstandards.com	China	11922	58
QUALITY CONTROL SOLUTIONS LTD.	0755-66853366; 13670046396	ORDERS@QCSRM.COM	China	24326	58
ChemStrong Scientific Co.,Ltd	0755-0755-66853366 13670046396	sales@chem-strong.com	China	18043	56
Shanghai Kewel Chemical Co., Ltd.	021-64609169 18901607656	greensnown@163.com	China	9906	50
Shanghai Lollane Biological Technology Co.,Ltd.	021-52996696，15000506266 15000506266		China	4512	55
Nanjing XiZe Biotechnology CO., Ltd.	025-66023220 0086-15250997978	1511893459@qq.com	China	7850	55
BOC Sciences	16314854226	info@bocsci.com	United States	9923	65
Amadis Chemical Company Limited	571-89925085	sales@amadischem.com	China	131957	58
Shenzhen Polymeri Biochemical Technology Co., Ltd.	+86-400-002-6226 +86-13028896684;	sales@rrkchem.com	China	57401	58

---

• (2S)-1-[[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrienyl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]oxoacetyl]-2-piperidinecarboxylic Acid
• (2S)?-1-?[2-?[(2R,?3R,?6S)?-?6-?[(2S,?3E,?5E,?7E,?9S,?11R)?-?2,?13-?Dimethoxy-?3,?9,?11-?trimethyl-?12-?oxo-?3,?5,?7-?tridecatrien-?1-?yl]?tetrahydro-?2-?hydroxy-?3-?methyl-?2H-?pyran-?2-?yl]?-?2-?oxo
• 2-Piperidinecarboxylic acid, 1-[2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrien-1-yl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]-2-oxoacetyl]-, (2S)-
• (S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)
• Everolimus Impurity 013-99
• Everolimus Related Compound
• Everolimus Impurity 3
• (2S)-1-[2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-Dimethoxy-3,9,11-trimethyl-12-oxo-3,5,7-tridecatrien-1-yl]tetrahydro-2-hydroxy-3-methyl-2H-pyran-2-yl]-2-oxoacetyl]-2-piperidinecarboxylic Acid
• Everolimus Impurity 3（013-99）
• (S)-1-(2-((2R,3R,6S)-6-((2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl)-2-hydroxy-3-methyltetrahydro-2H-pyran-2-yl)-2-oxoacetyl)piperidine-2-carboxylic acid? (Everolimus Impurity）
• Everolimus Impurity
• SECO RAPAMYCIN DEGRADATION PRODUCTS (RC 3)
• (2S)-1-{2-[(2R,3R,6S)-6-[(2S,3E,5E,7E,9S,11R)-2,13-dimethoxy-3,9,11-trimethyl-12-oxotrideca-3,5,7-trien-1-yl]-2-hydroxy-3-methyloxan-2-yl]-2-oxoacetyl}piperidine-2-carboxylic acid
• 147438-30-0